Featured

Status

Health Topics

Any Category
Chemicals and Drugs
Amino Acids, Peptides, and Proteins
Proteins
Clear Filters

Search Clinical Trials

44 Results
Not Yet Recruiting
Neoadjuvant Durvalumab and Tremelimumab With and Without Chemotherapy for Mesothelioma
Study Design: The study will be a two-arm, randomized non-comparative Phase Ib/IIa study of induction dual immunotherapy with durvalumab/tremelimumab OR platinum chemotherapy (cisplatin or carboplatin) and pemetrexed chemotherapy plus dual …
Baylor Role: Lead Sponsor
Active, Not Recruiting
Eltrombopag vs Standard Front Line Management for Newly Diagnosed Immune Thrombocytopenia (ITP) in Children
This is a prospective, open label, randomized, two-arm, multi-center Phase 3 trial. Patients with newly diagnosed ITP are randomized 2:1 to receive the experimental treatment, eltrombopag, or investigator's choice of …
Baylor Role: Lead Sponsor
Terminated
A Window of Opportunity Trial: Avelumab in Non-metastatic Muscle Invasive Bladder Cancer
Avelumab is a fully human monoclonal PD-L1 antibody of the immunoglobulin G1 (IgG1) subclass. It works by binding to PD-L1 on tumor cells, immune cells and/or stromal cells. This prevents …
Baylor Role: Lead Sponsor
Completed
Safety of Fresolimumab in the Treatment of Osteogenesis Imperfecta
Osteogenesis Imperfecta (OI) is a rare disorder that causes bones to break easily. People with OI may have broken bones with little or no trauma, dentinogenesis imperfecta (DI), and, in …
Baylor Role: Lead Sponsor
Recruiting
Autologous T-Cells Expressing a Second Generation CAR for Treatment of T-Cell Malignancies Expressing CD5 Antigen
To make the T cells the investigators will take blood from the patient or from the previous bone marrow transplant donor and stimulate it with growth factors to make the …
Baylor Role: Lead Sponsor
Completed
MEDI4736 Or MEDI4736 + Tremelimumab In Surgically Resectable Malignant Pleural Mesothelioma
Subjects with MPM will undergo surgical mediastinal lymph node biopsy (cervical mediastinoscopy) and simultaneous surgical biopsy of the pleural tumor by thoracoscopy, at which time tumor tissue (at least 2 …
Baylor Role: Lead Sponsor
Completed
Nivolumab With Epstein Barr Virus Specific T Cells (EBVSTS), Relapsed/Refractory EBV Positive Lymphoma (PREVALE)
The investigators will draw blood from the subject to make EBV-specific cytotoxic T-lymphocytes (EBVSTs) in the lab. Investigators will make the cells by first growing a special type of cells …
Baylor Role: Lead Sponsor
Completed
Rapid Infusion Rituximab, Hematologic, Oncologic, and Rheumatologic Disorders
The standard of care in patients receiving rituximab is to give the dose slowly and gradually increase the rate of rituximab until the full dose is given, which may take …
Baylor Role: Lead Sponsor
Completed
Dose Adjusted EPOCH-R, to Treat Mature B Cell Malignancies
The subject will need to have a variety of tests, exams, or procedures to find out if s/he can be on the study. The subject will also require placement of …
Baylor Role: Lead Sponsor
Active, Not Recruiting
Radiation- and Alkylator-free Bone Marrow Transplantation Regimen for Patients With Dyskeratosis Congenita
Dyskeratosis congenita (DC) is an inherited multisystem disorder, which classically presents with a clinical triad of skin pigment abnormalities, nail dystrophy, and oral leukoplakia. DC is part of a spectrum …
Baylor Role: Collaborator